Raffaella Pasquale

Raffaella Pasquale

Auto-generated profile, based on publicly available information

Raffaella Pasquale

Laboratory of Pharmacogenomics, CROM-Istituto Nazionale Tumori "Fondazione G. Pascale"-IRCCS, Naples, Italy

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Translational Lung Cancer Research
Verified
Journal Article
Closed access
PDF file
FFFrancesca Fenizia
Francesca Fenizia
RPRaffaella Pasquale
Raffaella Pasquale
CRCristin Roma
Cristin Roma
FBFrancesca Bergantino
Francesca Bergantino
AIAlessia Iannaccone
Alessia Iannaccone
NNNicola Normanno
Nicola Normanno
The introduction in the clinic of immune checkpoint inhibitors (IOs) has represented an important improvement for the treatment of patients with advanced non-small cell lung cancer (NSCLC). These drugs have shown a higher activity as compared with chemotherapy in both first- and second-line of treatment, with some patients experiencing a long-lasting response. More recently, combinations of IOs have entered clinical trials in different tumor types including NSCLC. Nevertheless, IOs are active only in a subgroup of patients and biomarkers for appropriate patients’ selection are urgently needed to offer the patients an effective therapy, and also to manage the costs. Tumor mutation burden (TMB) has powerfully emerged as a potential biomarker for immunotherapy and might enter the clinic in the next months, although different challenges are still unsolved. Different methods exist to evaluate TMB in tissue, ranging from whole exome sequencing (WES) to targeted sequencing of smaller sets of genes, which need to be fully standardized to ensure that patients receive an appropriate TMB test with clear clinical interpretation. In addition, as already happened for the implementation of liquid biopsy testing from NSCLC patients to identify targetable alterations, researchers are also evaluating the possibility to calculate TMB in blood, to further enlarge the number of NSCLC patients who may benefit from immunotherapy. Preliminary data highlight the difficulty to develop targeted sequencing panels for the assessment of TMB starting from the circulating cell free DNA (cfDNA). The applicability of TMB testing on liquid biopsy needs further investigation and may be clarified within the ongoing clinical trials.

19 July 2016 in Oncotarget
Verified
Journal Article
Open access
ARAnna Maria Rachiglio
Anna Maria Rachiglio
RARiziero Esposito Abate
Riziero Esposito Abate
ASAlessandra Sacco
Alessandra Sacco
RPRaffaella Pasquale
Raffaella Pasquale
FFFrancesca Fenizia
Francesca Fenizia
NNNicola Normanno
Nicola Normanno
Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma

4 June 2015 in Future Oncology
Verified
Journal Article
Closed access
FFFrancesca Fenizia
Francesca Fenizia
Antonella De LucaAntonella De Luca
Antonella De Luca
RPRaffaella Pasquale
Raffaella Pasquale
ASAlessandra Sacco
Alessandra Sacco
LFLaura Forgione
Laura Forgione
NNNicola Normanno
Nicola Normanno
The presence of EGFR mutations predicts the sensitivity to EGF receptor (EGFR)-tyrosine kinase inhibitors in a molecularly defined subset of non-small-cell lung carcinoma (NSCLC) patients. For this reason, EGFR testing of NSCLC is required to provide personalized treatment options and better outcomes for NSCLC patients. As surgery specimens are not available in the majority of NSCLC, other currently available DNA sources are small biopsies and cytological samples, providing however limited and low-quality material. In order to address this issue, the use of surrogate sources of DNA, such as blood, serum and plasma samples, which often contains circulating free tumor DNA or circulating tumor cells, is emerging as a new strategy for tumor genotyping.

18 September 2012 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
NNNicola Normanno
Nicola Normanno
ARAnna Maria Rachiglio
Anna Maria Rachiglio
CRCristin Roma
Cristin Roma
FFFrancesca Fenizia
Francesca Fenizia
CEClaudia Esposito
Claudia Esposito
Antonella De LucaAntonella De Luca
Antonella De Luca

1 December 2013 in Cancer Biology & Therapy
Verified
Journal Article
Open access
CEClaudia Esposito
Claudia Esposito
ARAnna Maria Rachiglio
Anna Maria Rachiglio
MPMaria Libera La Porta
Maria Libera La Porta
ASAlessandra Sacco
Alessandra Sacco
CRCristin Roma
Cristin Roma
NNNicola Normanno
Nicola Normanno
The activity of the epidermal growth factor receptor (EGFR) antibodies cetuximab and panitumumab in metastatic colorectal carcinoma (mCRC) is significantly limited by molecular mechanisms leading to intrinsic or acquired resistance. The S492R mutation of the EGFR, which is caused by either the 1476C>A or the 1474A>C substitution, interferes with binding to cetuximab but not to panitumumab, and has been detected in mCRC with acquired resistance to cetuximab. Since mechanisms of acquired and intrinsic resistance to EGFR monoclonal antibodies in CRC significantly overlap, we evaluated the frequency of the S492R mutation in a series of KRAS-exon 2 wild-type CRC patients. Genomic DNA was extracted from formalin fixed paraffin embedded (FFPE) tissues that were obtained from 505 systemic therapy-naïve CRC patients. A PCR/sequencing method for the detection of the S492R mutation was developed, by using as positive control a plasmid in which the 1474A>C mutation was generated by site directed mutagenesis. The lowe...

1 January 2013 in BioMed Research International
Verified
Journal Article
Open access
PDF file
CRCristin Roma
Cristin Roma
CEClaudia Esposito
Claudia Esposito
ARAnna Maria Rachiglio
Anna Maria Rachiglio
RPRaffaella Pasquale
Raffaella Pasquale
AIAlessia Iannaccone
Alessia Iannaccone
NNNicola Normanno
Nicola Normanno
Epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer (NSCLC) are predictive of response to treatment with tyrosine kinase inhibitors. Competitive Allele-Specific TaqMan PCR (castPCR) is a highly sensitive and specific technology. EGFR mutations were assessed by TaqMan Mutation Detection Assays (TMDA) based on castPCR technology in 64 tumor samples: a training set of 30 NSCLC and 6 colorectal carcinoma (CRC) samples and a validation set of 28 NSCLC cases. The sensitivity and specificity of this method were compared with routine diagnostic techniques including direct sequencing and the EGFR Therascreen RGQ kit. Analysis of the training set allowed the identification of the threshold value for data analysis (0.2); the maximum cycle threshold (Ct=37); and the cut-off ΔCt value (7) for the EGFR TMDA. By using these parameters, castPCR technology identified both training and validation set EGFR mutations with similar frequency as compared with the Therascreen kit. Sequencing detected rare mutations that are not identified by either castPCR or Therascreen, but in samples with low tumor cell content it failed to detect common mutations that were revealed by real-time PCR based methods. In conclusion, our data suggest that castPCR is highly sensitive and specific to detect EGFR mutations in NSCLC clinical samples.